Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

All NewsJune 12, 2026

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran’s profile against rusfertide.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT